Johnson & Johnson

The phase III IMROZ trial found that adding isatuximab to bortezomib, lenalidomide, and dexamethasone (VRd) significantly reduced disease progression or death by 40% and doubled sustained MRD negativity rates in transplant-ineligible newly diagnosed multiple myeloma patients ≤ 80 years old, establishing isatuximab/VRd as a new standard of care.

Global Nanopharmaceuticals Market expected to grow from USD 7.5 Billion in 2023 to USD 259.2 Billion by 2032, driven by advantages like enhanced bioavailability, targeted delivery, and reduced side effects. North America leads with USD 25.3 Billion in 2023. Nanopharmaceuticals revolutionize drug delivery, addressing complex diseases and overcoming traditional therapy limitations.

Johnson & Johnson submitted two sBLAs to the FDA to expand TREMFYA® use for pediatric patients with moderate-to-severe plaque psoriasis (6+ years) and active juvenile psoriatic arthritis (5+ years), based on Phase 3 PROTOSTAR study data and PK extrapolation from adult studies.

Formycon AG and MS Pharma enter licensing and supply agreement for FYB202/ustekinumab biosimilar in MENA region. MS Pharma to commercialize and produce FYB202 locally in Saudi Arabia. Formycon retains rights for MENA region after licensing FYB202 globally to Fresenius Kabi in 2023.

Johnson & Johnson presents TECVAYLI data from MajesTEC-5 and MajesTEC-4 studies, showing potential in newly diagnosed multiple myeloma patients. Results include MRD negativity and manageable safety profiles, with further combination therapy analysis planned in MajesTEC-7.

Subcutaneous daratumumab significantly improved PFS and OS vs active monitoring in high-risk smoldering multiple myeloma, reducing progression risk by 51% and death risk by 48%.

The Oncology Market is critical in global healthcare, driven by cancer prevalence, technological advancements, and strategic collaborations. Key players like Daiichi Sankyo, Bayer AG, and others innovate in diagnostics, treatments, and precision medicine. Market growth is fueled by R&D investments, sustainability focus, and consumer awareness. Challenges include regulatory constraints and talent shortages. Technological integrations like AI and IoT enhance patient care and operational efficiency.

TECVAYLI® (teclistamab-cqyv) shows potential as frontline therapy for newly diagnosed multiple myeloma, achieving 100% MRD negativity in MajesTEC-5 and MajesTEC-4 studies. Data presented at 2024 ASH Annual Meeting highlight promising efficacy and manageable safety profile.

Janssen-Cilag announces TECVAYLI® (teclistamab) data from MajesTEC-5 and MajesTEC-4 studies, showing 100% MRD negativity in newly diagnosed multiple myeloma patients, presented at 2024 ASH Annual Meeting.

Johnson & Johnson announces TECVAYLI® (teclistamab-cqyv) data showing 100% MRD negativity in newly diagnosed multiple myeloma patients treated with MajesTEC-5 induction and MajesTEC-4 maintenance therapies, presented at the 2024 ASH Annual Meeting.